Search research articles
Contact Us
Filters
Showing results (341-350 of 743) with videos related to
Page
of 75
Sort By:
Pediatric Dermatology
|
February 26, 2013
Dermatofibrosarcoma protuberans in childhood treated with slow Mohs micrographic surgery
Marjam J Barysch, Lisa Weibel, Kathrin Neuhaus, et al.
Journal of Dermatological Science
|
March 4, 2014
Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages
Samuel Gehrke, Atsushi Otsuka, Roman Huber, et al.
Cancer Cell
|
January 22, 2021
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte, Aizhan Tastanova, Zsolt Balázs, et al.
ESMO Open
|
August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma
Reinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
Cancers
|
July 9, 2022
Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <i>Cancers</i> 2021, <i>13</i>, 3830
Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2018
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients
Michael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, et al.
Cancers
|
August 7, 2021
Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
The Oncologist
|
June 1, 2017
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart, Selina Thurneysen, Elisabeth Rushing, et al.
Nature Communications
|
December 8, 2011
Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response
Maria Antsiferova, Marcel Huber, Michael Meyer, et al.
Clinical Proteomics
|
March 16, 2018
Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
Nina Zila, Andrea Bileck, Besnik Muqaku, et al.
Page
of 75
Search research articles
Search
Showing results (341-350 of 743) with videos related to
Sort By:
Page
of 75
Pediatric Dermatology
|
February 26, 2013
Dermatofibrosarcoma protuberans in childhood treated with slow Mohs micrographic surgery
Marjam J Barysch, Lisa Weibel, Kathrin Neuhaus, et al.
Journal of Dermatological Science
|
March 4, 2014
Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages
Samuel Gehrke, Atsushi Otsuka, Roman Huber, et al.
Cancer Cell
|
January 22, 2021
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte, Aizhan Tastanova, Zsolt Balázs, et al.
ESMO Open
|
August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma
Reinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
Cancers
|
July 9, 2022
Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <i>Cancers</i> 2021, <i>13</i>, 3830
Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2018
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients
Michael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, et al.
Cancers
|
August 7, 2021
Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
The Oncologist
|
June 1, 2017
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart, Selina Thurneysen, Elisabeth Rushing, et al.
Nature Communications
|
December 8, 2011
Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response
Maria Antsiferova, Marcel Huber, Michael Meyer, et al.
Clinical Proteomics
|
March 16, 2018
Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
Nina Zila, Andrea Bileck, Besnik Muqaku, et al.
Page
of 75